ACT_590953/2023
METHOD AND PRODUCT FOR LOCALISED OR SPATIAL DETECTION OF NUCLEIC ACID IN A TISSUE SAMPLE
10x Genomics, Inc. obtained a preliminary injunction before the Düsseldorf Local Division against Curio Bioscience Inc. for infringement of EP 2 697 391 B1 (spatial transcriptomics array patent), restraining Curio from offering, marketing, using or possessing the infringing arrays in Germany, France and Sweden. The court found all urgency and infringement conditions met, applied a purposive claim construction to the array claims, and confirmed that grossly negligent ignorance of infringement is equivalent to actual knowledge for timing purposes. The injunction was conditional on 10x Genomics providing EUR 2,000,000 security.
10x Genomics has sufficient standing to bring the action based on registration in the respective national patent registers; this creates a rebuttable presumption reversing the burden of proof
ClaimantLegal basis: R. 8.5(c) RoPNote: Court held that once applicant demonstrates registration in national registers, it is for the defendant to rebut the presumption of entitlement.
Infringement of EP 2 697 391 B1 (spatial transcriptomics array patent) by Curio Bioscience's arrays in Germany, France and Sweden
ClaimantLegal basis: Art. 25(a) UPCANote: Court found infringement and granted the preliminary injunction restraining Curio from offering, marketing or using the infringing spatial transcriptomics arrays in the three territories.
Stated purposes in patent claims indirectly define subject matter protected — product must not only fulfil spatial-physical features but be designed for the stated purpose
ClaimantLegal basis: Art. 69 EPC; purposive claim constructionNote: Court accepted this purposive interpretation, which helped confirm that Curio's arrays fell within the scope of the claim.
Grossly negligent ignorance or wilful blindness to infringement is equivalent to positive knowledge for the purposes of calculating the urgency clock
ClaimantLegal basis: UPC case law on knowledge of infringementNote: Court accepted that a patent holder who becomes aware of circumstances suggesting infringement must take readily available steps to investigate; failure to do so constitutes negligent ignorance equivalent to knowledge.
Request to order Curio Bioscience to compensate 10x Genomics for reputational and other damages incurred as a result of the proceedings
RespondentReason: Rejected by the court without detailed reasoning visible in the excerpt.
Request by 10x Genomics for defendant to provide security for anticipated litigation costs
ClaimantLegal basis: Art. 69(4) EPC; R. 158 RoP; R. 211.1(d) RoPReason: Rejected; in urgent provisional measure proceedings, R. 211.1(d) RoP precludes the need for such security given the urgent nature of the proceedings. Art. 69(4) EPC provides security for costs only for claimant, while R. 158 RoP extends this to both parties, but in urgent proceedings there is neither scope nor need for analogous application.
Browse other cases on this principle.
EP 2 697 391 B1 claims an array for localised detection of nucleic acid in a tissue sample. The array comprises a substrate with multiple species of capture probes immobilised such that each species occupies a distinct position, with a free 3' end, each capture probe comprising a positional domain and a capture domain including a Poly-T DNA oligonucleotide of at least 10 deoxythymidine residues. The court applied purposive claim construction, holding that 'stated purposes' in patent claims (here, the purpose of localised/spatial nucleic acid detection) indirectly define the subject matter protected by requiring that the product be designed for that stated purpose.